BG
SPRO icon

Bollard Group’s Spero Therapeutics SPRO Stock Holding History

Bollard Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,215
Closed -$19K – 402
2022
Q1 		$19K Hold
2,215
– – ﹤0.01% 387
2021
Q4 		$35K Hold
2,215
– – ﹤0.01% 371
2021
Q3 		$41K Hold
2,215
– – ﹤0.01% 361
2021
Q2 		$31K Hold
2,215
– – ﹤0.01% 375
2021
Q1 		$33K Hold
2,215
– – ﹤0.01% 372
2020
Q4 		$43K Hold
2,215
– – ﹤0.01% 350
2020
Q3 		$25K Hold
2,215
– – ﹤0.01% 372
2020
Q2 		$30K Buy
+2,215
New +$24.9K ﹤0.01% 389

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bollard Group's SPRO Position: Q2 2022 in Review

Bollard Group sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 2,215 shares — an estimated $19K sold.

Bollard Group first reported a position in SPRO in Q2 2020 and held it in 8 quarters. The position peaked at $43K in Q4 2020. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Bollard Group reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 2,215 Spero Therapeutics shares in Q2 2022, an estimated $19K.
  • Bollard Group first reported a position in Spero Therapeutics in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Spero Therapeutics position peaked at $43K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.